# Assessment of Serum Ferritin, TIBC and Kidney Function Test in Multitransfused Thalassemic Children

## Meena Varma, Jaidev Singh\* and Sangeeta Paneri

Deparment of Biochemistry M.G.M. Medical College, Indore, India.

(Received: 27 August 2010; accepted: 07 October 2010)

Beta thalassemia is a single gene disorder requiring regular multi-blood transfusions which causes serious side effects, as an overload of iron in the form of ferritin. We determined whether thalassemia could account for abnormal cation transport system. Traditionally serum iron, ferritin, TIBC and the % saturation, an indirect measurement of transferrin, have been used to determine iron status. The present study included 100 multitransfused thalassemic children and 35 control, in the age group of 3-10 years. Serum ferritin was evaluated by ELISA method, urea by Berthelot method, creatinine by Jaffes reaction & TIBC by Ramsay Dipyridyl method. It has been found that the serum ferritin level was significantly increased in thalassemic children as compared to control due to the regular blood transfusions. Serum kidney enzymes were also deranged. Serum ferritin, urea & creatinine levels increased and TIBC decreased. As the number of blood transfusion increases, the serum ferritin, urea & creatinine also significantly increased serum ferritin, urea, creatinine and decreased TIBC levels are associated with multi-transfused children.

Key words: Beta thalassemia, Kidney function test, Multi-blood transfusions.

Thalassemia major is the commonest hereditary form of transfusion dependent anemia<sup>1</sup>. Thalassemia syndrome is characterized by defect in the synthesis of one or more of the globin chains that form the hemoglobin tetramer<sup>2</sup>. In  $\beta$ thalassemia the production of  $\beta$  chains is inadequate.  $\beta$ -thalassemia major is a single gene disorder requiring regular multi blood transfusion which causes serious side effects as an overload of iron in the form of ferritin<sup>3-6</sup>. Excess or free iron can catalyze the formation of very toxic compounds such as OH~ radicals, through Fenton reaction which causes oxidative damage. This oxidative damage causes the pathogenesis of the membrane abnormalities observed in beta thalassemia. Iron overload may cause deposition of iron in hepatic parenchyma and other tissues like kidney and pancreas within a year of transfusion. As the iron overloading progresses the capacity of transferrin to bind and detoxify the iron may exceed and now non tranferrin bound fraction of plasma iron may promote the generation of free hydroxyl radicals, propagators of oxygen related damage7. The free radicals, generated can damage cellular membrane proteins and DNA resulting in wide ranging impairment in cellular function and integrity<sup>8</sup>. This manifests as cirrhosis & kidney dysfunction which is most common mode of death9.

<sup>\*</sup> To whom all correspondence should be addressed. E-mail: jsingh.gmc@gmail.com Jaidev\_singh26@yahoo.com

## VARMA et al.: STUDY OF BETA THALASSEMIA

Assessment of S. Ferritin level can give idea regarding starting of chelation therapy, which will reduce the concentration of Ferritin and is effective in preventing iron induced tissue injury and prolong life expectancy. Present work has been designed to assess the effect of the multitransfusion on various organs through estimation of S. Ferritin, TIBC, urea, and creatinine.

## MATERIAL AND METHODS

The study was carried out at the Department of Biochemistry, with the collaboration of Department of Pediatrics. Volunteer patients diagnosed with Thalassemia Major in the clinics of the department were selected for the study. Blood was obtained from 100 morbid and 25 healthy control children. All were in the age group 3-18 years.

## **Inclusion criteria**

Al1	patients	were	suffering	from	beta
thala	assemia m	najor.			

All patients had received more than 15 transfusions.

The patients who were suffering from any major disease were excluded.

The blood collected was allowed to clot and then centrifuged to obtain serum for the estimation of biochemical parameters.

Urea were estimated by Berthelot method<sup>10</sup>. Creatinine by Jaffes reaction<sup>11</sup>. TIBC by Ramsay Dipyridyl Method<sup>12</sup> and serum Ferritin was estimated by ELISA method<sup>13</sup>.

Values have been expressed as Mean  $\pm$  SD. The results were analyzed using Student't' test. P<0.05 was considered as significant.

Table 1. Serum values of all biochemical parameters of control and morbid groups

S. No.	Parameters	Control	Thalassemic
1. 2	Ferritin [µg/l] TIBC [µg/dl]	$79.04 \pm 20.11$ $342.34 \pm 47.99$	$4228.92 \pm 1827.40$ $323.37 \pm 37.0$
3.	Urea [mg/dl]	$30.20 \pm 8.24$	$48.20 \pm 11.20$
4.	Creatinine [mg/dl]	$0.65\pm0.20$	$1.30 \pm 0.30$

Table 2. Serum values according to ferritin level in thalassemic group

S.	Ferritin	No. of	Mean ± SD		
No.	Level µg/l	patients	TIBC [µg/dl]	Urea [mg/dl]	Creatinine [mg/dl]
1. 2.	720 - 4000(<4000) 4000 - 8000(>4000)	48 52	$324.0 \pm 42.3$ $322.7 \pm 32.1$	$47.3 \pm 10.24$ $49.0 \pm 11.24$	$\begin{array}{c} 1. \ 1 \pm 0.10 \\ 1.3 \pm 0.20 \end{array}$

Table 3. Mean values According to No. of Blood transfusions

No. of blood	No. of	Mean ± SD				
transfusions	patients	TIBC [µg/dl]	Ferritin [µg/l]	Urea [mg/dl]	Creatinine [mg/dl]	
< 100 > 100	60 40	$327.5 \pm 39.4$ $317.1 \pm 33.0$	$\begin{array}{c} 2990.5 \pm 109.24 \\ 6086.4 \pm 856.6 \end{array}$	$\begin{array}{c} 46.28 \pm 8.24 \\ 49.10 \pm 9.28 \end{array}$	$1.2 \pm 0.10$ $1.3 \pm 0.20$	

J. Pure & Appl. Microbiol., 5(1), April 2011.

#### **RESULTS AND DISCUSSION**

The study group comprised of 100 children of beta thalassemia. In present study it was found that the serum ferritin level was significantly (p<0.001) increased in thalassemic children as compared to control (Table 1), due to the regular blood transfusions. It has been previously reported by Pootrakul (1981), <sup>14</sup> George (1994), <sup>15</sup> Fargion (1982), <sup>16</sup> Dubey (2004) <sup>17</sup>.

As ferritin level increased, urea & creatinine also increased and TIBC decreased (Table 2). It was also observed that as the number of blood transfusions increases, the serum ferritin concentration was also significantly (p<0.001) increased. Urea & creatinine also increases and TIBC decreases (Table 3). Ali *et.al* (2008) <sup>21</sup> reported that, in 50 children with thalassemia had higher serum creatinine and urea values.

Mean serum value of TIBC was found to be decreased as compare to control group. It has been previously reported by CLP<sup>18</sup> (1995), Finch<sup>19</sup> (1982) & Tenchben<sup>20</sup> (1991) that the decrease TIBC level are associated with the iron overload or thalassemic patients.

Jain (1983), (Gunn, 1972)<sup>22</sup>, Olivlero (1994)<sup>23</sup> reported that patients with more transfusions have lower TIBC levels while urea, creatinine and ferritin level grater than the patients who had less transfusions.

## CONCLUSION

It can be concluded from the present study that increased serum ferritin, urea, creatinine and decreased TIBC levels are associated with multi-transfusions in children. Thalassemia major is a serious genetic disease but its diagnosable treatable and curable. Multitransfusions lead to iron overload in the form of ferritin which may be the cause for the development of the alteration of the various biochemical parameters. Timely intervention with chelation therapy can decrease the effect of iron over load and increase the life expectancy of the patients.

#### ACKNOWLEDGEMENTS

Special thanks to Dr. (Mrs) Meena Varma, Dr. Sangeeta Paneri, Dr. Amrit Kaur and Himanshu Sarathe.

#### REFERENCES

- Li ck. Current status of thalassemia major in Hong Kong :20<sup>th</sup> anniversary special issue. Hong Kong: Cooley Anemia.Association 2001.
- 2. RS Balgin. The Burden of haemoglobinopathies in India and the challenges a head: *Current science*. 2000; **79**(11).
- Fosburg MT, Nathana DG. Treatment of Cooley's anemia. *Blood.* 1990; 76: 435-444.
- Olivieri NF, Brittehum GM. Iron chelating therapy and the treatment of thalassemia. Blood, 1997; 89: 739-761.
- 5. http:// globin.cse.psu.edu.Haemoglobinopathy and thalassemia.
- Bayo A, Cao A, Derkaleustain V, et.al. Memorandum from the WHO meeting. WHO Bull. 1983; 61: 63-80.
- Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann N Y Acad Sci 1998; 856: 191-201.
- Britton RS, Leicerter KL, Bacon BR. Iron toxicity and chelation therapy. *Int J Haematol*. 2002; 76(3): 219-28.
- 9. Agarwal MB. Living with Thalassemia; Bombay Bhilani book Depot 1996.
- 10. Bowers Id chin, Che. 1986; **26**: P55-56.
- 11. Trinder P.Ann Clin Biochem. 1969; 6: 24.
- 12. Young, DS, et. al Clin. chem 1975; 21: 1D.
- Harold Varrley Practical Clinical Biochemistry 4<sup>th</sup> ed.page No.475-476.
- Pootrakaul P, Vongsmasa V, La ongpanich P, Wasi P. Serum ferritin levels in thalassemias and the effects of spienctomy. *Acta Haematol* 1981; 66(4): 244-50.
- George E, Wong HB, George R, Ariffin WA. Serum ferritin concentrations in transfusion dependent beta thalassemia. *Singapore Med J* 1994; **35**(1): 62- 4.
- Fargon S, Taddel MT, Gabutti V,Piga A, Di Palma A,Capra L, Fontanelli G, Avanzini A. Early iron overload in beta thalassemia major; When to start chelation therapy? *Arch Dis Child* 1982; 57(12): 929-33.
- 17. Dubey A.P, Agarwal H and Sudha S. Study of carbohydrate homeostasis in thalassemic children. Pedicon 2004 Jan:Serila N0. 29: no 91

J. Pure & Appl. Microbiol., 5(1), April 2011.

- CLP: Guidelines for the use of serum tests of iron stores. June 1995.
- Finch CA and Huberg H: Perspectives in iron metabolism. N. Engl J Med. 1982; 306(25): 1520-8.
- Temenboin M and Yatscoff RW : The total iron binding capacity in iron Poisoning. Is it useful? *AM J Dis child*; 1991; 145(4): 437-9.
- 21. Darakhshar Ali, Karimi Meharan, Abdolkarim

2008; 19(2): 206-209

- Gunn; R.B, D.N.Silver and W.F Rosce 1972 Potassieum permeability in b-thalassemia minor red blood cells. J. Clinical Investigation, 51: 1044 – 1049.
- 23. Oliviero O, Weia De Franoerchi, D. Mario et al : Oxidative damage and Erythrocytes membrane transport abnormalities in thalassemia. *Blood*, 1994; **84**: 315-320.

484